Loading...
Please wait, while we are loading the content...
Similar Documents
Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment
| Content Provider | Scilit |
|---|---|
| Author | Weisler, Richard H. Ota, Ai Tsuneyoshi, Kana Perry, Pamela Weiller, Emmanuelle Baker, Ross A. Sheehan, David V. |
| Copyright Year | 2016 |
| Description | Journal: Journal of affective disorders BackgroundMajor depressive disorder (MDD) is a common, debilitating disorder with substantial socioeconomic burden. Many patients with MDD experience symptoms that impair functioning and productivity, often negatively affecting work or educational pursuits. This Phase 3b open-label study evaluated adjunctive brexpiprazole in young adults with MDD, who were in work or study.MethodsYoung patients (18–35 years) with MDD (inadequate responders to 1–3 antidepressant treatments [ADT] for their current episode) received brexpiprazole 1–3mg/day (target dose, 2mg/day) adjunctive to the same stable dose of ADT for 12 weeks.ResultsDepressive symptoms improved during treatment with adjunctive brexpiprazole (primary endpoint, least squares [LS] mean change from baseline in Montgomery-Åsberg Depression Rating Scale [MADRS] total score, −18.1 [p<0.0001]). Reductions from baseline in Sheehan Disability Scale Score (SDS; LS mean change −11.2 [p<0.0001]) and Work Limitations Questionnaire (WLQ; p<0.0001) indicated improvements in the effects of patients' symptoms on functioning (work/school, social life, and home responsibilities). Changes from baseline in additional measures supported improvements in patient functioning and depression symptoms. The most common adverse events were headache (21.3%), weight increase (17.0%), and somnolence (17.0%); reported rates of akathisia were low (6.4%). Clinically relevant increases in weight (≥7%) occurred in 10.5% of patients.LimitationsOpen-label design; absence of comparator.ConclusionsBrexpiprazole may represent an effective therapy for adjunctive treatment strategy of young adults with MDD who are working or studying. The observed improvements in work/school functioning in patients with MDD, whose depression was treated with ADT+brexpiprazole, suggests potential to reduce socioeconomic burden |
| Related Links | https://core.ac.uk/download/pdf/82405675.pdf http://www.jad-journal.com/article/S0165032715312696/pdf |
| Ending Page | 47 |
| Page Count | 8 |
| Starting Page | 40 |
| ISSN | 01650327 |
| e-ISSN | 15732517 |
| DOI | 10.1016/j.jad.2016.06.001 |
| Journal | Journal of affective disorders |
| Volume Number | 204 |
| Language | English |
| Publisher | Elsevier BV |
| Publisher Date | 2016-06-04 |
| Access Restriction | Open |
| Subject Keyword | Journal: Journal of affective disorders Psychiatry and Mental Health Major Depressive Disorder |
| Content Type | Text |
| Resource Type | Article |
| Subject | Clinical Psychology Psychiatry and Mental Health |
